Induction Chemotherapy and Chemoradiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer: A Single-Institution Review of Two Different Regimens


KOCAK M., OZKAN A., Mayadagli A. , PARLAK C., Bilici A., Seker M. , et al.

CLINICAL LUNG CANCER, cilt.10, ss.124-129, 2009 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 10 Konu: 2
  • Basım Tarihi: 2009
  • Doi Numarası: 10.3816/clc.2009.n.016
  • Dergi Adı: CLINICAL LUNG CANCER
  • Sayfa Sayısı: ss.124-129

Özet

Purpose: We compared 2 different chemotherapeutic agents in combination with cisplatin as induction chemotherapy (ICT) followed by chemoradiation therapy (CHRT) in patients with inoperable locally advanced non-small-cell lung cancer (NSCLC). Patients and Methods: A total of 90 patients with inoperable locally advanced NSCLC received 3 courses of ICT consisting of gemcitabine 1200 mg/m(2) on day 1 and day 8 every 3 weeks and cisplatin 75 mg/m(2) on day 1 every 3 weeks (group 1; n = 39) or docetaxel 75 mg/m(2) on day 1 every 3 weeks and cisplatin 75 mg/m(2) on day 1 every 3 weeks (group 2; n = 51) followed by CHRT (docetaxel 30 mg/m(2) every week and cisplatin 20 mg/m(2) every week with 6600 cGy radiation therapy). Results: After the ICT, the response rate for group 2 (88.2%) was significantly higher than that of the gemcitabine-cisplatin arm (64.1%; P = .017). The response assessment performed on first month after CHRT revealed statistical difference for objective response rate in group 2 when compared with group 1 (P = .04). At the median follow-up of 15.7 months (range, 5-36 months), median overall survival (OS) was 12 months in group 1 (95% CI, 9.1-14.8) and 29.9 months in group 2 (95% CI, 16-43). Median progression-free survival (PFS) was 8 months in group 1 and 15 months in group 2. There was statistically significant difference between the 2 groups regarding OS and PFS (P = .043). Conclusion: Our results suggest that OS, PFS, and local control rate are significantly improved with ICT consisting of docetaxel and cisplatin when compared with gemcitabine-cisplatin in inoperable locally advanced NSCLC.